GB2448627A - Combination therapy and antibody panels - Google Patents
Combination therapy and antibody panelsInfo
- Publication number
- GB2448627A GB2448627A GB0812408A GB0812408A GB2448627A GB 2448627 A GB2448627 A GB 2448627A GB 0812408 A GB0812408 A GB 0812408A GB 0812408 A GB0812408 A GB 0812408A GB 2448627 A GB2448627 A GB 2448627A
- Authority
- GB
- United Kingdom
- Prior art keywords
- immunoglobulin
- combination immunotherapy
- combination therapy
- idiotypic
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 238000011220 combination immunotherapy Methods 0.000 abstract 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000003211 malignant effect Effects 0.000 abstract 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 abstract 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 abstract 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention is related to combination immunotherapy for malignancies such as Non-Hodgkin's Lymphoma (NHL) and chronic lymphocytic leukemia (CLL). In one embodiment, the combination immunotherapy first provides for the administration of a monoclonal antibody, or antibody fragment, directed to a non-idiotypic portion of an immunoglobulin or immunoglobulin-like molecule expressed on the surface of a malignant cell (e.g., a framework region of a variable region). The combination immunotherapy next provides for the administration of an immunogenic composition comprising at least a portion of the same malignant cell surface immunoglobulin, whether an idiotypic portion or non-idiotypic portion.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/297,167 US20070134248A1 (en) | 2005-12-08 | 2005-12-08 | Combination therapy and antibody panels |
US11/297,168 US20070134249A1 (en) | 2005-12-08 | 2005-12-08 | Combination therapy and antibody panels |
PCT/US2006/047077 WO2007067780A2 (en) | 2005-12-08 | 2006-12-08 | Combination therapy and antibody panels |
Publications (3)
Publication Number | Publication Date |
---|---|
GB0812408D0 GB0812408D0 (en) | 2008-08-13 |
GB2448627A true GB2448627A (en) | 2008-10-22 |
GB2448627B GB2448627B (en) | 2010-07-14 |
Family
ID=38123554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0812408A Expired - Fee Related GB2448627B (en) | 2005-12-08 | 2008-07-07 | Combination therapy and antibody panels |
Country Status (3)
Country | Link |
---|---|
CA (1) | CA2632744A1 (en) |
GB (1) | GB2448627B (en) |
WO (1) | WO2007067780A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2922212B1 (en) * | 2007-10-11 | 2011-11-11 | France Etat | ANTIBODY ANTIBODY |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5227159A (en) * | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
US20030129628A1 (en) * | 1992-03-09 | 2003-07-10 | Sybille Muller | Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease |
US6706484B1 (en) * | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
-
2006
- 2006-12-08 WO PCT/US2006/047077 patent/WO2007067780A2/en active Application Filing
- 2006-12-08 CA CA002632744A patent/CA2632744A1/en not_active Abandoned
-
2008
- 2008-07-07 GB GB0812408A patent/GB2448627B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5227159A (en) * | 1989-01-31 | 1993-07-13 | Miller Richard A | Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies |
US20030129628A1 (en) * | 1992-03-09 | 2003-07-10 | Sybille Muller | Anti-idiotypic antibody and its use in diagnosis and therapy in HIV-related disease |
US6706484B1 (en) * | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
Non-Patent Citations (3)
Title |
---|
Blood, Vol.88, 1996, Nelson, et al., "Tunour-specific, cytotoxic T-lymphocytes...", pp.580-589 * |
Blood, Vol.92, 1998, Davis, et al., "Anti-Idiotype antibodies can induce...", pp.1184-1190 * |
Haematologica, Vol.87, 2002, Ruffini, et al ., "Idiotypic vaccination for B-cell...", pp.989-1001 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007067780A2 (en) | 2007-06-14 |
GB2448627B (en) | 2010-07-14 |
GB0812408D0 (en) | 2008-08-13 |
CA2632744A1 (en) | 2007-06-14 |
WO2007067780A3 (en) | 2008-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
DE602005016773D1 (en) | ANTIBODY ANTIBODIES WITH REDUCED COMPLEMENT FIXATION | |
ATE535547T1 (en) | CROSS-LINKED ANTIBODIES | |
CL2010000788A1 (en) | Monoclonal antibody or antigen binding fragment thereof that binds to integrin alpha-v-beta-6; pharmaceutical composition that includes it; use to treat or prevent fibrosis, psoriasis, cancer, acute lung damage and alpont syndrome; use to detect integrin alfa-v-beta-6 (div. sol. no. 513-03). | |
IL244803B (en) | Humanized anti-beta7 antibodies and uses therefor | |
CY1111622T1 (en) | ANTI-CMET HUMANIZED COMPETITORS | |
TW200833713A (en) | Human antibodies that bind CD19 and uses thereof | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
WO2004005470A3 (en) | Antibodies to non-shed muc1 and muc16, and uses thereof | |
PL2097453T3 (en) | Monoclonal antibodies against the human anti-müllerian hormone type ii receptor (amhr-ii) | |
WO2003072036A3 (en) | Treatment methods using anti-cd22 antibodies | |
TW200510459A (en) | RG1 antibodies and uses thereof | |
UA114879C2 (en) | CD38 ANTIBODY FOR CANCER TREATMENT | |
WO2005000901A3 (en) | Cd20-specific antibodies and methods of employing same | |
ATE526987T1 (en) | DR5 ANTIBODIES AND THEIR USE | |
WO2003048328A3 (en) | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen | |
ATE513857T1 (en) | CELL SURFACE GLYCOPROTEINS FROM OVARY CANCER CELLS AND MYELOMA CELLS, THEIR ANTIBODIES AND USES THEREOF | |
HK1074670A1 (en) | Sets of digital antibodies directed against short epitopes, and methods using same | |
SI1572087T1 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
ATE517920T1 (en) | HUMANIZED ANTIBODIES AGAINST INTERFERON ALPHA RECEPTOR-1 (IFNAR-1) | |
WO2006029220A3 (en) | Combination therapy with anti-ctla4 and anti-4-1bb antibodies | |
EA200970884A1 (en) | METHODS OF TREATING CANCER BY INTRODUCING HUMAN INTERLEUKIN IL-18 COMBINATIONS | |
WO2008100563A3 (en) | Compositions and methods for diagnosing and treating cancer | |
GB2448627A (en) | Combination therapy and antibody panels | |
WO2007075706A3 (en) | Affinity optimized epha2 agonistic antibodies and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20141208 |